Monte Rosa Therapeutics (GLUE) Capital Expenditures (2020 - 2026)

Monte Rosa Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 800.0% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.6 million (up 510.33% YoY), while the FY2025 annual figure was $149000.0, up 198.0% from the prior year.
• Capital Expenditures for Q1 2026 stood at $2.7 million, up from -$290000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $17.8 million in Q4 2023, with the low at -$14.4 million in Q3 2023.
• The 5-year median for Capital Expenditures is $983000.0 (2024), against an average of $2.1 million.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures soared 4391.03% in 2023, then sank 812.53% in 2025.
• Monte Rosa Therapeutics' Capital Expenditures stood at $8.2 million in 2022, then soared by 117.76% to $17.8 million in 2023, then sank by 121.13% to -$3.8 million in 2024, then soared by 92.28% to -$290000.0 in 2025, then surged by 1043.45% to $2.7 million in 2026.
• Business Quant data shows GLUE's Capital Expenditures at $2.7 million in Q1 2026, -$290000.0 in Q4 2025, and -$2.8 million in Q3 2025.